Highly Efficient Micro-Scale Liquid-Liquid In-Flow Extraction of 99mTc from Molybdenum

The trend to achieve even more compact-sized systems is leading to the development of micro-scale reactors (lab-on-chip) in the field of radiochemical separation and radiopharmaceutical production. Technetium-99m extraction from both high and low specific activity molybdenum could be simply performed by MEK-driven solvent extraction if it were not for unpractical automation. The aim of this work is to develop a solvent extraction and separation process of technetium from molybdenum in a micro-scale in-flow chemistry regime with the aid of a capillary loop and a membrane-based separator, respectively. The developed system is able to extract and separate quantitatively and selectively (91.0 ± 1.8% decay corrected) the [^99mTc]TcO₄Na in about 20 min, by using a ZAIPUT separator device. In conclusion, we demonstrated for the first time in our knowledge the high efficiency of a MEK-based solvent extraction process of ^99mTc from a molybdenum-based liquid phased in an in-flow micro-scale regime.     

Separation of no-carrier-added 99mTcO4 − from 99Mo–99mTc equilibrium mixture by PEG based aqueous biphasic separation technique using sodium/potassium salts of citric and tartaric acid

Extraction and separation of no-carrier-added (nca) ^99mTcO₄ ^? from ⁹⁹Mo–^99mTc equilibrium mixture was carried out by environmentally benign polyethylene glycol based liquid–liquid aqueous biphasic systems (ABS) consisting various inorganic salts. Among the various inorganic salt trisodium citrate and potassium sodium tartrate showed the suitable salt rich phase for the best separation in this report. The concentration variation of salt rich phase, temperature and PEG phase also exhaustively studied in paper for the achievement of high separation factor. At 40 °C temperature in 50 % (w/v) PEG-4000-2M Na₃citrate showed the highest separation factor (S _Tc/Mo) 1.2 × 10⁷.     

Preparation and biodistribution study of technetium-99m-labeled quercetin as a potential radical scavenging agent

Free radicals and oxidative stress are the primary causes of several chronic diseases such as cancer and heart disease. Quercetin is a natural compound with potent antioxidant activity. We have prepared and evaluated technetium-99m (^99mTc)-labeled quercetin as a potential radical scavenging radiotracer. A ^99mTc-quercetin complex was prepared using quercetin, SnCl₂ and Na^99mTcO₄ in a buffered solution over 30 min. The participation coefficient was measured in octanol and queues solutions. The stability was determined in phosphate buffered saline and serum. The biodistribution in normal mice was evaluated at 0.5, 2, 6 and 24 h post-injection. The radiochemical purity (>99%) was determined by thin layer chromatography (TLC) in normal saline solution as the mobile phase. It has a log P of 0.204. It was mainly cleared by the kidneys and showed negligible brain uptake at four time points measured post-injection. The pharmacological properties of quercetin, mainly its free radical scavenging, may potentially cat as a radiopharmaceutical agent for radical-targeted imaging of tissue with high levels of reactive oxygen species.     

99mTc-ceftriaxone, as a targeting radiopharmaceutical for scintigraphic imaging of infectious foci due to Staphylococcus aureus in mouse model

^99mTc-labeled antibiotics have opened an exciting field of research in infectious diseases diagnosis. Direct labeling of ceftriaxone with ^99mTc was carried out using the various amounts of ceftriaxone and SnCl₂·2H₂O at different pH and incubation time intervals to find the highest radiochemistry efficiency with high stability at room temperature and human blood serum. ITLC-SG and HPLC were performed to measure the radiochemical purity of the conjugate. The binding study showed 45 % specific binding to Staphylococcus aureus. The biodistribution study and scintigraphic imaging showed the localization of ^99mTc-ceftriaxone at the site of infection in comparison with normal and inflamed muscles with high sensitivity and specificity in mouse model. The results showed that ^99mTc-ceftriaxone is a promising candidate as a targeting radiopharmaceutical for Staphylococcal infection imaging in humans which needs further investigations.     

Simulation of chlorination reaction behavior of hull wastes by using the HSC code

Nitrofurantoin (NFN) radiolabeling with technetium-99m (^99mTc) was investigated using different concentration of the NFN, sodium pertechnetate (Na^99mTcO₄), reducing agent (SnCl₂) at different pH ranges (5.1–6.00). The suitability of the ^99mTc-NFN was evaluated in terms of the radiochemical purity (RCP) yield, in vitro stability in saline, serum, in vitro binding with E. coli, biodistribution in E. coli infected model rat (ERT), and scintigraphic accuracy in E. coli infected model rabbit (EBT). The superlative radiochemical succumb at 2.5 mg NFN, 125 μL of SnCl₂ (1 μg/μL in 0.01 N HCl), 2.5 mCi of Na^99mTcO₄, at pH 5.2 at 30, 60, 90, and 120 min after reconstitution was 64.50 ± 0.11, 97.50 ± 0.16, 94.25 ± 0.10, 92.15 ± 0.14 and 90.75 ± 0.0.13%. The complex was found stable in saline and serum for 90% up to 120 min and showed 50–65% in vitro binding with E. coli. The absorption of the ^99mTc-NFN, primarily at E. Coli infected (ECT) muscle of ERT was lower but after 60 min it went up to 7.25 ± 0.17%. The absorption in the blood, liver, spleen, stomach, intestines, inflamed muscle (N.T1) and normal muscle (N.T2) went down while in the kidney and urine it went up with time. The ratio of the ECT/N.T1 was 7:1 and N.T2/N.T1 was 2:1. The Whole Body Static (WBS) imaging of the ERB confirmed the suitability of the ^99mTc-NFN as radiotracer. The superlative radiochemical succumb, significant in vitro stability in saline and serum, in vitro binding with E. coli, ideal biodistribution and scintigraphic accuracy confirmed the viability of the ^99mTc-NFN as radiotracer for infection.     

The case for fractional solubility profiles

This work reports the synthesis, radiolabeling and preliminary biodistribution results in tumor-bearing mice of [^99mTc(CO)₃(PA-TZ-CHC)]⁺. The novel colchicine (CHC) ligand was successfully synthesized via “click” reaction. Radiolabeling was performed in high yield with [^99mTc(CO)₃]⁺ core to get [^99mTc(CO)₃(PA-TZ-CHC)]⁺, which was hydrophilic and cationic, and was stable at room temperature. Biodistribution studies in tumor-bearing mice showed that [^99mTc(CO)₃(PA-TZ-CHC)]⁺ accumulated in the tumor with good uptake while comparatively low retention. The clearance of the ^99mTc-complex from normal organs was fast, resulting in increasing tumor/blood and tumor/muscle ratios. The promising results in preliminary biodistribution studies warrant further research to improve tumor targeting efficacy and pharmacokinetic profile of radiolabeled CHC derivative by structural modification.     

Preparation of 99Mo/99mTc generator based on alumina 99Mo-molybdate (VI) gel

In this work alumina ⁹⁹Mo-molybdate (VI) gel is evaluated as a column matrix for use in the preparation of small chromatographic column type ^99mTc generator. Alumina molybdate (VI) gel is prepared by dissolving inactive MoO₃ with aluminum foil in 5 M NaOH solution containing ⁹⁹Mo radiotracer. After complete dissolution, 0.5 H₂O₂ was added to the reaction mixture solution and acidified to pH 5.5 with concentrated HNO₃. The formed AlMo precipitate was washed with NaNO₃ solution, dried at 50 °C for 24 h and then packed in the form of a chromatographic column for elution of the generated ^99mTc radionuclide with physiological saline solution (0.9 % NaCl). Greater than 86 % of the generated ^99mTc activity is immediately and reproducibly eluted with passing 10 mL of the saline solution through 2.0 g of alumina ⁹⁹Mo-molybdate column bed at a flow rate of about 1.0 mL/min. The high radiochemical ≥98.6 % TcO₄ ^?, radionuclidic ≥99.90 % ^99mTc and chemical purities of the eluates satisfy the specifications for use in nuclear medicine.     

Synthesis and biological distribution of 99mTc–norfloxacin complex, a novel agent for detecting sites of infection

The optimization of the radiolabeling yield of ciprofloxacin analogous, norfloxacin, with technetium-99m (^99mTc) was described. Dependence of the labeling yield of ^99mTc–norfloxacin complex on the concentration of norfloxacin, SnCl₂·2H₂O content, pH of the reaction mixture and reaction time was studied. Norfloxacin was labeled with ^99mTc at pH 3 with a labeling yield of 95.4% by using 5 mg norfloxacin, 50 μg SnCl₂·2H₂O and 30 min reaction time. The formed ^99mTc–norfloxacin complex was stable for a time up to 3 h. Biological distribution of ^99mTc–norfloxacin complex was investigated in experimentally induced inflammation rats using Staphylococcus aureus (bacterial infection model) and heat killed Staphylococcus aureus and turpentine oil (sterile inflammation model). In case of bacterial infection, the T/NT value for ^99mTc–norfloxacin complex was found to be 6.9 ± 0.4 which was higher than that of the commercially available ^99mTc–ciprofloxacin under the same experimental condition.     

Syntheses of High‐Valent fac‐[99mTcO3]+ Complexes and [3+2] Cycloadditions with Alkenes in Water as a Direct Labelling Strategy

Reported herein is a new concept for the labelling of biomolecules with small [^{99 m}TcO₃]⁺ complexes through a [3+2] cycloaddition with alkenes for radiopharmaceutical applications. We developed convenient reactions for the synthesis of small, water stable fac‐[TcO₃(tacn‐R)]⁺ complexes (⁹⁹Tc and ^99mTc, tacn=1,4,7‐triazacyclononane, R=H, ‐CH₂‐C₆H₅, ‐CH₂‐C₆H₄COOH). With alkenes, these high valent [^99mTcO₃]⁺ complexes undergo [3+2] cycloaddition with formation of the corresponding Tc^V–glycolato complexes. The ^99mTc^V and ^99mTc^VII complexes are stable at 37 °C in water and in the presence of serum proteins. Therefore, new opportunities in technetium chemistry are enabled with a high potential for medicinal and biological applications. In contrast to classical labelling, the presented strategy is ligand and not metal‐centred.     

A simple and sensitive separation technique of 99Mo and 99mTc from their equilibrium mixture

The present work describes a simple and inexpensive separation method of ⁹⁹Mo from the equilibrium mixture. The liquid–liquid extraction technique has been employed to separate ⁹⁹Mo and ^99mTc using triisooctylamine (TIOA). The ⁹⁹Mo and ^99mTc were quantitatively separated out in 2 M TIOA with tripled distilled water; ^99mTc was back extracted from TIOA organic phase to aqueous phase by 0.1 M DTPA. The species information or indirect speciation of molybdenum was also established by the extraction profile of the molybdenum.     

A Freeze Dried Kit for 99mTc(V) Dimercaptosuccinic Acid

^99mTc pentavalent dimercaptosuccinic acid [^99mTc(V) DMSA], a useful agent for imaging thyroid medullary carcinoma and other tumors can be reliably prepared by addition of Na^99mTcO₄ to a freeze-dried mixture of DMSA and Sn (2:1 molar ratio). The radiochemical purity, stability and animal bio-distribution behaviour is similar to that of the agent made by addition of NaHCO₃ to DMSA (III) renal imaging freeze-dried kit.     

Preparation,molecular modeling and biodistribution of 99mTc-phytochlorin complex

Phytochlorin [21H, 23H-Porphine-7-propanoicacid, 3-carboxy-5-(carboxymethyl)13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetramethyl-,(7S,8S)] was labeled with ^99mTc and the factors affecting the labeling yield of ^99mTc-phytochlorin complex were studied in details. At pH 10, ^99mTc-phytochlorin complex was obtained with a high radiochemical yield of 98.4 ± 0.6 % by adding ^99mTc to 100 mg phytochlorin in the presence of 75 μg SnCl₂·2H₂O after 30 min reaction time. The molecular modeling study showed that the structure of ^99mTc-phytochlorin complex presents nearly linear HO–Tc–OH unit with an angle of 179.27° and a coplanar Tc(N1N2N3N4) unit. Biodistribution of ^99mTc-phytochlorin complex in tumor bearing mice showed high T/NT ratio (T/NT = 3.65 at 90 min post injection). This preclinical study showed that ^99mTc-phytochlorin complex is a potential selective radiotracer for solid tumor imaging and afford it as a new radiopharmaceutical suitable to proceed through the clinical trials for tumor imaging.     

Preparation of radioiodinated ritodrine as a potential agent for lung imaging

Ritodrine (a beta-2 adrenergic receptor agonist) was successfully labeled with ¹²⁵I via direct electrophilic substitution reaction at ambient temperature. ¹²⁵I-ritodrine was obtained with a maximum labeling yield of 97 ± 0.163 % and in vitro stability up to 24 h. Biodistribution studies showed that maximum in vivo uptake of ¹²⁵I-ritodrine in lungs was 20.4 ± 0.22 % injected activity/g tissue at 1 h post-injection, whereas the clearance from mice appeared to proceed mainly via the renal pathway. ¹²⁵I-ritodrine is not a blood product and so it is more safe than the currently available ^99mTc-MAA, and its lung uptake is higher than that of the recently discovered ^99mTc(CO)₅I and ^99mTc-DHPM. As a conclusion, radioiodinated ritodrine could be used as a novel radiopharmaceutical for lung perfusion scan safer than the currently available ^99mTc-MAA and more potential than the recently discovered ^99mTc(CO)₅I and ^99mTc-DHPM.     

Preparation and bioevaluation of <Superscript>99m</Superscript>Tc–carbonyl complex of guanine

The aim of this study is to prepare radiolabeled guanine with ^99mTc(CO)₃⁺ core. For this purpose, guanine has been radiolabeled with ^99mTc(CO)₃⁺ core. Quality control study of radiolabeled guanine molecule with ^99mTc(CO)₃⁺ core was performed by thin layer radio chromatography (TLRC) and high performance liquid radio chromatography (HPLRC). The results showed that the radiolabeling yield was quite high (94 ± 3%). Beside that ^99mTc(CO)₃–Gua complex has showed good in vitro stability during the 24 h period. Radiopharmaceutical potential of this complex was evaluated in Wistar Albino Rats. It was concluded that ^99mTc(CO)₃–Gua could be used as a nucleotide radiopharmaceutical for in vivo applications.     

Formulation and preclinical evaluation of 99mTc–gemcitabine as a novel radiopharmaceutical for solid tumor imaging

The aim of this study is the formulation of a new radiopharmaceutical for imaging solid tumor bearing. Gemcitabine is a nucleoside analogue used as chemotherapeutic agent. Gemcitabine was formulated and radiolabeled with one of the most important diagnostic radioactive isotopes (technetium-99m) to be investigated in solid tumor imaging. The labeling parameters such as gemcitabine amount, stannous chloride amount, pH of the reaction mixture, and reaction time were optimized. ^99mTc–gemcitabine was prepared at pH 9 with a maximum labeling yield of 96 ± 0.3 % without any notable decomposition at room temperature over a period of 8 h. The preclinical evaluation and biodistribution in solid tumor bearing mice showed that ^99mTc–gemcitabine had solid tumor selectivity, preclinical high biological accumulation in tumor cells and high retention. Tumor/normal muscle (T/NT) ratios increased with time showing high T/NT ratio (T/NT = 4.9 ± 0.27 at 120 min post injection) and high Tumor/Blood ratio (3.4 ± 0.06), suggesting ^99mTc–gemcitabine as a novel solid tumor imaging agent.     

Characterization of 99mTc(CO)3-iminodiacetic acid (IDA) and its comparison with 99mTc-(IDA)2 using compounds for hepatobiliary scintigraphy

The organometallic precursor of fac-[^99mTc(CO)₃(H₂O)₃]⁺ has attracted much attention because of the robustness and small size of Tc(I)-tricarbonyl complexes compared to Tc(V) complexes and the good labeling affinity with a variety of donor atoms. Among various ligand systems, an iminodiacetic acid (IDA) was proven as a good chelating group to form a Tc(III)-compelx as well as has been shown its potential as a chelating system for fac-[^99mTc(CO)₃] precursor. In an attempt to confirm the similarity and the difference between ^99mTc(CO)₃-IDA and ^99mTc-(IDA)₂-complex, M(CO)₃-IDA (M = ^99mTc, Re) complexes of disofenin, mebrofenin and N-(3-iodo-2,4,6-trimethyl phenylcarbamoylmethyl) iminodiacetic acid were prepared, and the biological evaluation of ^99mTc(CO)₃-disofenin was performed. The ^99mTc(CO)₃-IDA complexes were prepared with a high radiolabeling yield (>98%) in a quantitative manner and showed a negative charge. The in vivo pharmacokinetic behavior of ^99mTc(CO)₃-disofenin showed a similar biological activity to ^99mTc-(disofenin)₂ in that those complexes were quickly cleared from the blood by the hepatocytes and excreted into the gallbladder and intestine. Accordingly, the ^99mTc(CO)₃-IDA derivatives of disofenin and mebrofenin might be used as hepatobiliary imaging agents. Since an IDA is a promising chelator for ^99mTc-based radiopharmaceutical and the biological properties of ^99mTc(CO)₃-IDA derivative shows similar to that of ^99mTc-complex, a biomolecule containing IDA can be freely radiolabeled with fac-[^99mTc(CO)₃]-precursor or ^99mTc. However, the radiolabeling efficiency and the biological behavior demonstrates the favorable properties of ^99mTc(CO)₃-IDA compound for the development of a new imaging agent.     

Synthesis and evaluation of a phenylbenzothiazole-based 99mTc(CO)3-radiotracer for possible application in imaging of β-amyloid plaques in Alzheimer’s disease

The 2-phenyl benzothiazole pharmacophore is known to have high affinity for amyloid beta (Aβ) and is therefore derivatized, to [N-(4′-benzothiazol-pyridin-2-yl-methyl-amino)-acetic acid (BTPAA)] for radiolabeling with [^99mTc(CO)₃(H₂O)₃]⁺ precursor. The radiotracer, ^99mTc(CO)₃–BTPAA is evaluated in vitro and in vivo to determine its binding with the Aβ and ability to cross the blood brain barrier. The radiotracer prepared in >95 % radiochemical yield, showed ~25 % inhibition in presence of thioflavin-T, indicating its specificity towards aggregated Aβ protein. The radiotracer also showed brain uptake of 0.25 ± 0.04 % injected dose/g at 2 min post injection, indicating its ability to cross the blood brain barrier.     

S-bridged complex of <Superscript>99m</Superscript>Tc with <Emphasis Type="Italic">fac</Emphasis>(S)-[Rh(aet)<Subscript>3</Subscript>]: Quality control,characterization and biodistribution studies in rats

fac(S)-[Rh(aet)₃] (aet = 2-aminoethanethiolate) is N₃S₃ metalloligand which can coordinate to transition metal ions to form S-bridge polynuclear complexes. The reaction was carried out between ^99mTcO₄Na and fac(S)-[Rh(aet)₃] in the presence of SnCl₂·2H₂O. A complex analogous to [Re{Rh(aet₃)}₂]³⁺ is formed.⁶ A simple method for radiolabeling of fac(S)-[Rh(aet)₃] with ^99mTc has been developed and radiolabeling efficiency was higher than 99%. Effect of SnCl₂·2H₂O concentration, electrophoresis, HPLC, UV-Visible absorption spectra and biodistribution studies in rats were performed. Higher uptake by kidneys showed rapid distributions of the labeled fac(S)-[Rh(aet)₃]. Liver uptake was significant, stomach, lungs and intestine uptake was high at 4 hours post injection time.     

The stability of99mTc phosphorus compounds in plasma both in vivo and in vitro

The in vivo and in vitro stability of^99mTc hydroxyethlylidene diphosphonate, 99^mTc methylenediphosphonate and^99mTc pyrophosphate in plasma has been studied using paper chromatographic technique as the analytical tool. The results indicate that the amounts of^99mTc activity found both at the origin and R_f range of^99mTcO₄ ^? for in vivo experiments are slightly greater than those for either in vitro or control experiments. However, this amount of^99mTc activity represents about 0.16–0.4% of the injected dose. Therefore, it is suggested that^99mTc phosphorus radiopharmaceuticals are stable in vivo and neither oxidation nor hydrolysis of these bone imaging agents occurs in the blood.     

Preparation and biological distribution of 99mTc-cefazolin complex, a novel agent for detecting sites of infection

The optimization of the radiolabeling yield of cefazolin with ^99mTc was described. Dependence of the labeling yield of ^99mTc-cefazolin complex on the amounts of cefazolin and SnCl₂·2H₂O, pH and reaction time was studied. Cefazolin was labeled with ^99mTc with a labeling yield of 89.5 % by using 1 mg cefazolin, 5 μg SnCl₂·2H₂O at pH 4 and 30 min reaction time. The radiochemical purity of ^99mTc-cefazolin was evaluated with ITLC. The formed ^99mTc-cefazolin complex was stable for a time up to 3 h, after that the labeling yield decreased 64.0 % at 8 h. Biological distribution of ^99mTc-cefazolin complex was investigated in experimentally induced inflammation mice, in the left thigh, using Staphylococcus aureus (bacterial infection model) and turpentine oil (sterile inflammation model). Both thighs of the mice were dissected and counted and the ratio of bacterial infected thigh/contralateral thigh was then evaluated. In case of bacterial infection, T/NT for ^99mTc-cefazolin complex was 8.57 ± 0.4 after 0.5 h, which was higher than that of the commercially available ^99mTc-ciprofloxacin under the same experimental conditions. The ability of ^99mTc-cefazolin to differentiate between septic and aseptic inflammation indicates that ^99mTc-cefazolin could undergo further clinical trials to be used for imaging sites of infection.